There is an interesting implication of the comment on market penetration. Davis said penetration was "mid to high teens".
If we take that to be 16%:
125k * 16% = 20,000
Then revenue expectation for 20k patients, using annual WAC (price) of $36,468 and 80% GtN yields $583m revenue.
But guidance is $325m. And Q2 actual is $83.2m
Calcing the other direction:
Q2 revenue / (Q'ly WAC * GtN) = paying patients if full price
83.2m / (9,117 * 83%) = 10,995 patients
11k / 125k = 8.8% penetration
So ..... there must be alot of patients getting discounts and/or on free samples.